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were also compared in a single time point between a cohort of newly-diagnosed ET or PV patients and a second cohort comprised of patients who had been under hydroxyurea treatment for a median duration of 32 months. Lower amount of V617F allele was found in hydroxyurea-treated PV patients (44% versus 54% in PV patients analyzed at diagnosis) unlike in those with ET where the difference was minimal if at all. Interestingly, in both PV and ET, changes of V617F allele burden under hydroxyurea were more prominent in women than in males, suggesting a greater sensitivity to the drug of females. A significant decrease of JAK2V617F burden has been also documented in 72% of 18 patients (9 PV and 9 ET) considered by Ricksten et al; of note, only after four months of cytoreductive therapy with hydroxyurea the levels of mutant allele were significantly reduced compared to those pre-treatment 4 . JAK2 variance MUT ( % JAK2V617F in last sample -% JAK2V617F in baseline sample) : (% JAK2V617F in baseline sample x100) was calculated as a measure of relative changes in JAK2V617F allele burden between the baseline and follow-up sample 1, 2, 6 .
There were 104 pts with PV and 68 with ET; their median age was 56 yr (range, 15-84), 49% were females. The clinical characteristics at diagnosis are reported in Table 1 .
The median follow-up time was 3.1 years (range 0.6-26.1); no evolution to myelofibrosis or acute leukemia occurred. The median time elapsing from diagnosis to first ("baseline") PB sample was 9 months, 6 and 15 months in PV or ET, respectively. The median interval time between the baseline and the follow-up sample (considered as the last one in case of multiple samples) in the whole patient population was 27 months (range 6-60), 28 and 23 months for PV or ET, respectively. According to previous reports, the mean V617F burden was significantly greater in PV than in ET pts (50 ± 26% and 32 ± 18%, respectively; P <0.0001).
Sixty-four patients, 40 with PV and 24 with ET remained chemotherapy-free during follow-up (Group 1); PV patients were managed with phlebotomies only plus low-dose aspirin, while ET patients had received no drug at all or low-dose aspirin. One-hundred eight patients (63%), accounting for 61% of PV and 65% of ET patients, respectively, had received cytoreductive treatment with hydroxyurea; of these, 44 patients were chemotherapy-naive and started therapy within two months after the basal blood sample was collected (Group 2) whereas 64 patients were already on treatment from a median of 57 (range 3-290) months at the time of first genotyping (Group 3).
In the group of untreated patients (Group 1) (Fig. 1A ) the median interval time between baseline and follow-up sample was 26 months (range 6-60) for PV patients and 24 months (range 6-59) for ET patients. The JAK2V617F allele burden remained stable during the follow-up period: it was 44% and 49% in the baseline and follow-up sample, respectively, in PV patients, and 27% and 31%, respectively, in ET patients. Therefore, we found no evidence for a time-dependent increase of V617F allele burden in untreated PV and ET patients in a medium-term follow-up (median of 26 months). As a matter of fact, in a previous study in ET patients we were able to document significantly raised levels of mutant allele compared to newly-diagnosed patients only in those who had a history of disease of at least ten years 7 .
Among patients belonging to Group 2, that included 24 PV and 20 ET patients, the median interval time between baseline and follow-up sample was 29 months (range 10-55)
for PV patients and 26 months (range 7-57) for ET patients. The JAK2V617F allele burden was 45% and 41% (P=0.7) in the baseline and follow-up sample in PV patients, respectively, and 38% and 35% in case of ET patients (P= .024) (Fig. 1B) . The individual JAK2V617F allele burden changes at the second time-point during continuous hydroxyurea treatment are reported in Table 2 . By using the criteria for evaluating "molecular response" in PV or ET that have been recently published by a European
LeukemiaNet consensus conference 8 we found that no patient with either PV or ET had a "complete response", i.e. the reduction of JAK2V617F allele burden to an undetectable level. A "partial response", i.e. a reduction of >50% from baseline in patients with <50%
mutant allele burden at baseline or a reduction of >25% in those with >50% at baseline, was observed in 3 ET patients (15%) and 3 PV patients (12%). On the contrary, in 5 ET (25%) patients the burden of V617F allele increased of a median percent value of 13%
(range, 8%-25%) while in 10 PV (41%) patients mutant allele burden increased of 70%
(range, 3%-900%)
In patients of Group 3 (Fig. 1C) , that included 40 PV and 24 ET patients, the median interval time between baseline and follow-up sample was 28 months for both PV (range 6-54) and ET patients (range 6-60). The JAK2V617F allele burden was 58% and 61% in the baseline and follow-up sample in PV patients, respectively, and 34% and 38% in case of ET pts (P=.039). Considering PV and ET patients all together, there was a statistically significant increase of the median value of V617F allele burden over time from 36% to 41% in the basal and the follow-up sample, respectively (P= .023, repeated measure test).
As a whole, when we considered patients receiving hydroxyurea we observed a low (less than 10%), yet statistically significant, reduction of V617F allele burden only in the group of newly treated ET patients, in accordance with another study 1 . When considering individual cases, a modification of mutated allele burden consistent with the definition of "partial response" according to the ELN criteria involved 15% of ET patients and 12% of PV patients in our series. Furthermore, the fact that the amount of V617F allele showed a tendency towards raising levels in ET and PV patients who were already under hydroxyurea at the time of baseline evaluation and remained continuously under drug for a median of 28 months (patients in Group 3) suggest that small changes of allele burden measured in patients of group 2 may be of little significance. Since only 6 patients showed a molecular response we did not attempt to correlate it with clinical parameters.
In summary, we conclude that in untreated patients with ET and PV changes in V617F allele burden occur very smoothly over years, making clinically uninformative and not cost-effective the routine serial quantitative determinations of V617F allele. However, in cases where the phenotype modifies suggesting evolution to post-PV/post-ET myelofibrosis, a comparison of allele burden with that measured at diagnosis might be worthwhile since increasing load of mutated JAK2 burden have been implicated in myelofibrotic transformation 9, 10 . Last, we confirmed previous reports that hydroxyurea can reduce the JAK2V617F allele burden in subsets of patients 1, 3, 4 . However, we suggest that serial determination of V617F allele burden in patients receiving hydroxyurea should be reserved to clinical studies since its role in routine patient management remains unclear. Statistically significant differences, tested by the Wilcoxon matched-pairs signed-ranks test, between baseline and last samples, are reported in the figure.
